Teva Pharmaceuticals USA, Inc. and Glenmark
Pharmaceuticals Inc., USA have agreed to the terms demanded by the
Department of Justice to resolve price-fixing charges against the
companies, a scheme that affected the prices of several critical
generic drugs.
According to the DOJ, these are the first
resolutions in this litigation that require companies to divest
their pravastatin-related products. Pravastatin is a widely used
cholesterol treatment medicine.
- Israel-based Teva must pay $225 million in what DOJ says is the largest ever against a domestic antitrust cartel.
- Teva also must donate $50 million in other drugs to people in need, drugs also affected by the scheme. These drugs are the antifungal clotrimazole (sold by Bayer under the brand name Lotrimin), and the antibiotic, tobramycin.
- Glenmark, based in India, must pay $30 million.
- Prior defendants: Apotex Inc. admitted its role in this conspiracy and agreed to pay a $24.1 million penalty in May 2020. Taro Pharmaceuticals U.S.A. Inc., and its former executive Ara Aprahamian Taro admitted to its role in the conspiracy. Taro was penalized $205.7 million in July 2020. Aprahamian is awaiting trial. Sandoz Inc. admitted to its role in fixing the price of cystic fibrosis medicine tobramycin and other treatments and was penalized $195 million. A former Sandoz executive pleaded guilty.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.